VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > ASCEND Cardio is a Leading Provider of Cardio IT Solutions

<< Previous

Bullboard Posts

Next >>

Comment by jopatcloon Jul 15, 2024 11:12am

48 Views

Post# 36132950

RE:RE:RE:ASCEND Cardio is a Leading Provider of Cardio IT Solutions

Good comment on Ascend Cardivascular

 		@nicolaosK wouldnt it be just spectacular if Vpt gets $1,000 per month USD from all 50k usa hospitals that Asscend has their software in. This would be $822,000,000 cnd of saas revenue
 		4
 		24 minutes ago

 				 
@yudi@nicolaosK   + good sales and some sales (multiple) to trickle in this year.
 		0
 		20 minutes ago

 				 
@budmancubfan Not sure how the agreement is set up @nicolaosK, but that would be US$600,000,000. Imagine what kind of a sales premium would be tied to that in a buyout situation.
 		0
 		2 minutes ago

 				 
@yudi @cardinal? Next news? Sales or FDA V4.0?

 		@Synergy Dr Kai Thorsten Laser and other top Cardiologists I am sure eagerly await 4.0 @Rocket67 Key Takeaways from AEPC 2024: -VMS Strain and Heat Maps: Our demonstrations showcased how VMS+ visualization tools provide unparalleled insights into heart function. The precision and detail of our software impressed cardiologists from around the globe. Automated Plotting of Key Anatomical Landmarks: Attendees experienced firsthand how VMS+ simplifies and enhances cardiac assessments. The elimination of manual plotting streamlines the diagnostic process, increasing accuracy and reliability in volumetric measurements. 
 		3
 		about an hour ago

 				 
@Synergy I find the mixed messaging between Bart and Hugh amusing. Hugh telling us at shareholder conf call 3.2 is being sold hard as what is approved AND Bart apparently pre-selling VMS+ 4.0 starting hard in Portugal recently. I learned from investment in Covid Antibodies and Vaccines that Belgium, Holland and Denmark are the key centres for teaching hospitals providing staff training for much of continental Europe and Bart Hendriks would have his closest contacts in these regions. I therefore have been 100% sure of Ventripoint's success when we were chosen by Bart as worthy as the AI company he was looking to support. Dr Kai Thorsten Laser gave us a needed delay along with others and now VMS+ 4.0 should have no reason not to be adopted by some of these contacts on approval by the FDA, EU CE Mark and Health Canada etc...